Join Drs Camidge and Dagogo-Jack in Chicago as they discuss the latest information on MET-altered NSCLC. In this lively symposium, our expert faculty will explore the role of ADCs in the management of NSCLC, with a focus on cMET targeted agents. They will also cover MET-related activity as it relates to NSCLC and new therapeutic agents on the horizon. You don’t want to miss this exciting opportunity to interact with the experts!
MODERATOR
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology
University of Colorado Cancer Center
Aurora, Colorado
PANELIST
Ibiayi Dagogo-Jack, MD
Assistant Professor of Medicine
Harvard Medical School
Thoracic Oncologist
Internal Medicine/Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
6:45 pm
6:50 pm
7:10 pm
7:35 pm
7:45 pm
720 S Michigan Ave, Chicago, Illinois, 60605
Room: Continental A
Upon completion of this activity, participants will:
Have increased knowledge regarding the
Have greater competence related to
Demonstrate greater confidence in their ability to
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded up to 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-169-L01-P).